Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Nebulized budesonide for … - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Nebulized budesonide for the treatment of moderate to severe asthma in infants and toddlers.

Artikel i vetenskaplig tidskrift
Författare Göran Wennergren
S L Nordvall
G Hedlin
C Möller
S Wille
E Asbrink Nilsson
Publicerad i Acta paediatrica (Oslo, Norway : 1992)
Volym 85
Nummer/häfte 2
Sidor 183-9
ISSN 0803-5253
Publiceringsår 1996
Publicerad vid Institutionen för kvinnors och barns hälsa, Avdelningen för pediatrik
Sidor 183-9
Språk en
Länkar www.ncbi.nlm.nih.gov/entrez/query.f...
Ämnesord Administration, Inhalation, Asthma, drug therapy, Bronchodilator Agents, administration & dosage, therapeutic use, Budesonide, Child, Preschool, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Infant, Nebulizers and Vaporizers, Pregnenediones, administration & dosage, therapeutic use, Severity of Illness Index, Treatment Outcome
Ämneskategorier Pediatrik, Lungmedicin och allergi, Farmakologi

Sammanfattning

Maintenance treatment with nebulized budesonide was studied in young children with asthma not controlled without steroids. In a blind parallel-group study for 18 weeks, 102 children, mean age 22 (5- 47) months, were randomized for treatment starting with 0.25 or 1 mg b.i.d. The patients were reviewed every 3 weeks, and if symptom control had been achieved the dose was reduced, otherwise it was kept. The clinical effect was very good with both dose regimens. The median time to 7 consecutive days without any asthma symptoms was about 1 month with both, highlighting the importance of the duration of therapy rather than the benefits of a high starting dose. In 18 of 24 children who attained the placebo stage, symptoms had reappeared at the last visit. Although an overall minimal effective maintenance dose could not be demonstrated, 47% achieved symptom control on 0.25 mg b.i.d., i.e. fulfilled criteria for further dose reduction. No significant side effects were seen. On average, 25% of the nominal dose reached the patients.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?